T
HE CAPACITY AND reserve of the mammalian hematopoietic system are remarkable. This has been shown in animal studies by sequential transplantations of bone marrow-derived stem cells into lethally irradiated recipients.'.' There is also a plentiful supply of pluripotent stem cells and lineage-determined progenitor cells in humans to maintain adequate blood counts under normal conditions, but hematopoiesis can be severely compromised by cytotoxic chemotherapy and i~adiation.'.~ High-dose conditioning therapies that include total body irradiation (TBI) are notably myelotoxic and require the transplantation of hematopoietic progenitor cells.'" For the support of dose-escalated radiochemotherapy in cancer patients, blood-derived progenitor cells are increasingly used as a substitute for bone marrow."." Hematologic reconstitution in mice after lethal irradiation and bone marrow grafting was shown to evolve in several phases that are mediated by different progenitor cell subsets."' The ability of human blood-borne progenitor cells to reconstitute long-term hematopoiesis has been often questioned, as it was not clear whether peripheral blood contains early pluripotent stem cells, and if so, whether their numbers would be sufficient."."
To address the question of hematopoietic recovery and platelet recovery within less than 18 and 14 days, respectively. These numbers were also predictive for long-term reconstitution, indicating that normal blood counts are likely t o be achieved within less than 10 months after transplantation. Conversely, 12 patients were autografted with a median of 1.75 x lo4 CFU-GM per kilogram resulting in delayed recovery t o platelet counts of greater than 150 x 109/L between l and 6 years. Our study includes bone marrow examinations in 50 patients performed at a median follow-up time of 10 months (range, 1 t o 85 months) posttransplantation.
A comparison with normal volunteers showed a 3.2-fold smaller proportion of bone marrow CD34+ cells, which was paralleled by an even more pronounced reduction in the plating efficiency of CFU-GM and burst-forming unit-erythroid. No secondary graft failure was observed, even in patients autografted with relatively low numbers of progenitor cells. This suggests that either the pretransplant regimens were not myeloablative, allowing autochthonous recovery, or that a small number of cells capable of perpetual self-renewal were included in the autograft products. long-term reconstitution after peripheral blood progenitor cell (PBPC)-supported high-dose therapy, we examined 145 patients with hematologic malignancies who were autografted at our center within the last 9 years. PBPC were mobilized using conventional cytotoxic chemotherapy or cytokine-based regimens.
Follow-up examinations of bone marrow in 50 patients showed that posttransplant hematopoiesis is characterized by a significantly reduced number of hematopoietic progenitor cells when compared with healthy volunteers. Normal peripheral blood counts are maintained, and no graft failure has been observed in disease-free p"-tients.
MATERIALS AND METHODS

Patients
Between May 1985 and December 1993, a total of 145 patients with hematologic malignancies were included in the study."~'y The majority of patients autografted during the first 3 years of the observation period had acute myelogenous leukemia (AML), while the present transplantation protocols predominantly include patients with malignant lymphoma and multiple myeloma. Eighty-four patients were male and 61 female, with a median age of 37 years (range, 16 to S8 years). At the time of PBPC-supported high-dose therapy, 140 patients were in complete or partial remission, whereas five patients had active disease, The patient characteristics, including information on the high-dose conditioning regimens, are summarized in Table  I . All patients were treated at the Departments of Internal Medicine V and Radiology of the University of Heidelberg (Heidelberg, Germany). Informed consent was obtained from each patient before therapy. The study was conducted under the guidelines of the Joint Ethical Committee of the University of Heidelberg. The cut-off date of this report is June 30. 1994.
PBPCs were collected either after cytotoxic chemotherapy. in the course of steady-state administration of hematopoietic growth lactors, o r during cytokine-enhanced marrow recovery postchemotherapy. Twenty-nine patients had bone marrow involvement by histopathologic examination before the start of PBPC mobilization. The Table 2 .
Hematologic short-term reconstitution, as mostly observed during the patient's stay in the hospital, was defined as the time required to achieve a white blood cell (WBC) count of 21.0 X lo9& an absolute neutrophil count (ANC) of r 0 . 5 X lo9&, and an unsubstituted platelet count of 220 X 109L Patients were considered to have reached long-term reconstitution as soon as a hemoglobin level of 2 12.0 g/dL, a WBC count of 24.0 X 109/L, an ANC of 21.5 X IO'IL, and a platelet count of 2 150 X 109L were observed. As the majority of our patients were referred from other hospitals, follow-up examinations were also performed in those centers. For regular staging examinations, most of the patients were seen in our hospital at intervals of 3 to 6 months. In a group of 50 patients, we performed bone marrow examinations that included a clonogenic culture assay and immunophenotyping of hematopoietic progenitor cells. Samples of bone marrow and peripheral blood were obtained from 10 consenting normal volunteers for comparison. 
Collection of PBPCs and Cryopreservation
Harvesting was performed with a Fenwal CS 3000 (Baxter Deutschland GmbH, Miinchen, Germany). For 75 patients, a total nucleated cells (TNC) target quantity of 0.4 X 109kg was envisaged. PBPC collection was thereafter monitored by CD34+ cell assessment. In general, 10 L of blood was processed at a flow rate of 50 to 70 W m i n during each leukapheresis. The apheresis product was mixed with the same volume of minimal essential medium (MEM) containing 20% dimethylsulfoxide (DMSO Merck, Darmstadt, Germany). The final cell suspension was transferred into freezing bags (Delmed Inc. New Brunswick, NJ) and frozen to -100°C with a computer-controlled cryopreservation device (Cryoson BV-6, Cryoson Deutschland GmbH, Schollkrippen, Germany). The frozen cells were transferred into the liquid phase of nitrogen and stored at -196°C.
Clonogenic Assay for Hematopoietic Progenitor Cells
The concentration of hematopoietic progenitor cells in bone marrow, leukapheresis products, and peripheral blood was assessed using a semisolid clonogenic culture assay. In October 1990, a commercially available assay was introduced that was also used for the normal volunteers (Stemcell Technologies Inc, Vancouver, Canada). The culture medium consisted of 30% fetal calf serum, 10% medium conditioned by phytohemagglutinin-stimulated leukocytes (PHA-LCM), 1 IU recombinant human erythropoietin, 5 X IO-' mol& 2-mercaptoethanol, and 0.9% methylcellulose. The mononuclear cells (MNC) were plated in duplicate and incubated at 37°C and 5% CO, in humidified atmosphere. After 14 days, colonies were scored using an inverted microscope.
Imrnunojluorescence Staining and Flow Cytometry
For immunofluorescence analysis, 1 X lo6 MNC of bone marrow, leukapheresis products, and peripheral blood were incubated for 30 minutes at 4°C with the fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated monoclonal antibody (MoAb) HPCA-2 (CD34; Becton Dickinson, Heidelberg, Germany). After the MoAb incubation, the cells were washed twice with phosphate-buffered 
Pretransplantation Conditioning Regimen and Intensive Care Posttransplant
The pretransplantation conditioning therapy consisted of TBI, 14.4 Gy (hyperfractionated over 4 days), and cyclophosphamide in 74 patients. This regimen served as standard protocol for patients with acute leukemia and non-Hodgkin's lymphoma (NHL). In March 1992, the BEAM protocol was adopted for patients with high-grade NHL. Including two patients with low-grade NHL who were not eligible for TBI, 14 patients received BEAM. Forty-three patients with Hodgkin's disease were treated with CBV (cyclophosphamide 6.8 dm', etoposide 1,600 mg/m2, and carmustine 450 mg/m2; for the different dose-escalated regimens, see also Korbling et all6 and Haas et al"), and three patients with multiple myeloma underwent high-dose therapy with melphalan alone. Eleven patients received 140 mg/m2 melphalan with TBI.
All patients had prophylactic gut decontamination. Intravenous antibiotic therapy was administered for fever ~38.5"C, and amphotericin-B was added for documented fungal infection or persistent fever. A platelet count of more than 220 X 109L was maintained by HLA-A/-B-matched platelet transfusions, and red blood cells (RBC) were given when the hemoglobin level was below 8 g/dL.
Statistical Analysis
The clinical and laboratory data of the patients were analyzed according to standard statistical methods using a commercially available computer program (Statworks; Cricket Software, Philadelphia, PA). The relationship between the content of the autografts [TNC per kilogram, granulocyte-macrophage colony-forming units (CFU-GM) per kilogram, and CD34+ cells per kilogram] and the duration of short-term and long-term reconstitution was determined by simple linear regression and correlation analysis. To assess for statistical significance between grouped data of patients and normal volunteers, the Mann-Whitney U test was applied. A significance level of P < .OS was chosen.
RESULTS
Hematologic Reconstitution Afrer PBPC-Supporied HighDose Therapy
Short-term recovery.
The group of 145 patients presented here is heterogeneous except that all patients had hematologic malignancies and received blood-derived hematopoietic progenitor cells for the support of dose-escalated cytotoxic therapy. The autografts also add to the diversity, as PBPC were collected using different mobilization regimens.
Seven patients died of early transplantation-related complications, which translates into a mortality rate of 4.8%. The autografts of these patients contained a median 7.8-fold smaller number of CFU-GM per kilogram compared with the other 138 patients. Eleven patients relapsed between I and 8 months posttransplantation without having reconstituted. Interestingly, eight of these early relapses were observed in patients with AML autografted in first or second remission. It is questionable whether the term graft failure is appropriate for these cases, as recurrence of disease was interfering with the engraftment of reinfused normal progenitor cells.
Having excluded the patients with toxic death as well as those who did not engraft and who also experienced early relapse, a total of 127 patients were available for the evaluation of short-term reconstitution. The relationship between the number of hematopoietic progenitor cells reinfused and the time required for short-term reconstitution is best characterized by threshold numbers. Autografting of more than 2.5 X lo6 CD34+ cells per kilogram or 12.0 X l o 4 C m -G M per kilogram resulted in neutrophil and platelet recovery within less than 18 and 14 days, respectively (Fig 1) . In contrast, the number of TNC transplanted per kilogram had no predictive quality.
There was a remarkable difference between the patient groups with regard to the amount of CFU-GM autografted per kilogram. For instance, maximum numbers were observed in patients with low-grade NHL whose transplants contained a median S f o l d greater quantity of CFU-GM per kilogram compared with patients with AML. As shown in Fig 2, patients with low-grade NHL had shorter times of neutrophil and platelet recovery.
Another point relates to the history of five patients with AML who received mafosfamide-purged bone marrow between 39 and 228 days (median, 98 days) after PBPC-supported high-dose therapy, because they showed no signs of reconstitution. Two patients achieved stable long-term reconstitution and are in complete remission, one patient died of a hemolytic-uremic syndrome, and two patients relapsed.
Long-term recovery. We continue with the long-term follow-up of the 127 patients who achieved early trilineage engraftment. While reconstitution data are not available for nine patients, one patient died of toxoplasma gondii encephalitis 97 days after PBPC autografting. We also observed one case of myelodysplasia 39 months posttransplantation in a patient with follicular lymphoma autografted in second remission with as few as 0.93 x IO4 CFU-GM per kilogram.
Twenty-three patients relapsed between 1 and 25 months (median, 5 months) after PBPC-supported high-dose therapy without having reached normal blood counts. In the case of palliative chemotherapy, hematologic recovery was further compromised by tumor progression and treatment-related myelotoxicity. On the other hand, one relapsed patient with AML and one with Hodgkin's disease were successfully treated using second-line cytotoxic chemotherapy, which was accompanied by recovery to normal blood counts. 
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For the evaluation of long-term recovery, a total of 93 patients are eligible. Erythroid, neutrophil, and platelet recovery were closely related to each other, suggesting recovery from a common ancestor cell (Fig 3) . Compared with neutrophils, the time variation to normalization of platelet counts was more pronounced. Therefore, we concentrated on the kinetics of platelet long-term recovery as the critical cell lineage. The same threshold numbers then emerged as described above for early reconstitution. Patients autografted with more than 2.5 X IO" CD34' cells per kilogram and 12.0 X IO' CFU-GM per kilogram, respectively. developed platelet counts of more than 150 X IO"/L within less than IO months of transplantation (Fig 4) .
When early platelet recovery was delayed, a longer time was needed to achieve normal counts above 150 X IO"/L (Fig S ) . Delayed recovery with a time span between 1 and 6 years was observed in six patients with Hodgkin's disease, in five patients with AML, and in one patient with low-grade NHL. The PBPC autografts of these 12 patients contained a median of only I .75 X IOJ CFU-GM per kilogram (range. 0.21 X 10' to 4.9 X IO' per kilogram), while six of them received a TBI-containing high-dose regimen. In summary, none of the 9 3 patients assessable developed graft failure. with a maximum follow-up time of 9 years. We are also not aware of any temporary decrease in the peripheral blood counts signifying a compromised hematopoiesis. Table 3 ).
The concentration of CD34" cells tended to be greater in BM samples of patients who had received large numbers of CD34' cells. However, the relationship between these two parameters was moderate at best. considering a correlation coefficient of only R = 3 1 . It was interesting to find that the time elapsed between PBPC-supported high-dose therapy and the BM examination was not related to the number of CFU-GM, BFU-E. or CD34" cells in the BM samples.
DISCUSSION
We present data on the hematopoietic recovery of Days following PBPCT tain long-term hematopoiesis has been questioned."*'* The PBPC mobilization regimens included cytokines in the majority of cases, which is worth mentioning as granulocytemacrophage colony-stimulating factor (GM-CSF), for instance, was considered potentially harmful because of its differentiation-inducing effect on pluripotent stem cells.20 With a maximum follow-up time of 9 years, we have not observed secondary or subsequent graft failure in a group of 93 patients assessable for long-term reconstitution. The longest observation period for a patient mobilized using a cytokine-containing regimen is 66 months. The evaluation of long-term reconstitution included 51 patients who received TB1 as part of the high-dose conditioning therapy. Hematopoietic failure was observed in one patient with follicular lymphoma who was autografted in second remission using GM-CSF-mobilized PBPCs. The patient never recovered to normal blood counts and developed a myelodysplastic syndrome 39 months postgrafting. The very low number of CFU-GM contained within the patient's autograft already indicated a hematopoiesis that was severely compromised before the high-dose therapy. Recent analyses suggest an increased risk of developing myelodysplasia after autologous bone marrow transplantation in patients with malignant lymphoma. Actuarial incidence rates between 6.4% and 18% at 2 to 6 years were
The data presented here show how the hematopoietic content of the autografts affects the rapidity of marrow recovery. Short-term reconstitution was clearly related to the number of progenitor cells transplanted. Both CFU-GM and CD34' cells were predictive for rapid neutrophil and platelet recovery, with threshold quantities of 2.5 X 10' CD34+ cells per kilogram and 12.0 X lo4 CFU-GM per kilogram, respectively. These figures are consistent with the data of other cent er^.^^.'^ Reinfusing more progenitor cells did not result in faster recovery, suggesting that marrow sites for homing and proliferation are limited. To further shorten the period of severe aplasia, precursor cells of later developmental stages would be needed.27 The seven patients who died of early transplantation-related complications received significantly fewer CFU-GM per kilogram compared with the other 138 patients. At first glance, this finding provides a strong argument to aim at harvests containing at least the threshold numbers. However, only one patient with severe lung bleeding died of a complication precipitated by prolonged pancytopenia. The other patients died of toxic organ failures apparently not related to bleeding or infections. A low yield of hematopoietic progenitor cells may be, therefore, considered as a more general risk factor of early death.
The threshold numbers of progenitor cells derived from the analysis of early reconstitution were also valid for late reconstitution. All patients autografted with at least 2.5 X 10' CD34+ cells per kilogram and 12.0 X lo4 CFU-GM per kilogram, respectively, developed normal blood counts within less than 10 months after transplantation. Except for one patient, delayed recovery was confined to patients with acute leukemia and Hodgkin's disease, reflecting the fact that patients with high-grade NHL. Moreover, mutual dependence exists not only between diagnosis, the cytotoxic pretreatment, and the PBPC mobilization modality, but includes also the pretransplant conditioning therapy. All patients with Hodgkin's disease, for example, received the CBV regimen. while patients with acute leukemias underwent high-dose therapy with cyclophosphamide and TBI.
The role of additional BM grafting in the setting of PBPC transplantation can be briefly addressed. From the observation in five patients, we conclude that reinfusion of BM after PBPC autografting had no influence on the kinetics l 1101 100 J I .
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Months following PBPCT For personal use only. on August 16, 2017. by guest www.bloodjournal.org From of hematopoietic recovery, It is conceivable that either the number of viable progenitor cells reinfused was criticdly low or engraftment was insufficient due to the lack of an immediately preceding conditioning therapy." The latter explanation is less likely, as marrow cells could be successfully engrafted in syngeneic mice without cytotoxic pretreatment."
The fact that we have seen no graft failure even in patients transplanted with extremely low numbers of CFU-GM or CD34' cells suggests a stem cell not extinguishable by the pretransplant conditioning regimens. Although the low PBPC yields in those patients already indicated a severely compromised hematopoiesis, long-term recovery was eventually achieved despite the substantial myelotoxicity added by the pretransplant therapy. Posttransplantation hematopoiesis may then result to some degree from reinfused progenitor cells as well as from surviving pluripotent stem cells. This view is consistent with the detection of chimerism after allogeneic bone marrow transplantation."'.'' If autochthonous recovery is possible even after TBI-containing high-dose regimens, there would be no rationale for reinfusing higher amounts of progenitor cells than the threshold numbers. However, it is conceivable that an increased number of progenitor cells might reduce the risk of myelodysplastic syndrome. In the setting of syngeneic or allogeneic PBPC grafting, a greater amount of progenitor cells might be also advantageous for the competition with eventually surviving stem cells of the recipient.'*.'' This mechanism could be synergistically effective with a T-cell-mediated inhibition of host-derived hematopoiesis.
Whether reinfused progenitor cells contribute to long-term hematopoiesis or not, there is no question that posttransplantation hematopoiesis is maintained by a significantly lower number of progenitor cells compared with normal do- nors. A similar observation was made by Messner et al'4 in patients after allogeneic bone marrow transplantation. The investigators also observed an increased proportion of colony-forming cells in cell cycle to compensate for the smaller number of progenitor cells. It was interesting to note that the number of hematopoietic progenitor cells that we found in the BM samples posttransplantation was hardly related to the quantity of CD34+ cells and C m -G M transplanted. There was also no relationship between the concentration of progenitor cells and the time that had elapsed after PBPC autografting. Although hematopoiesis may not be evenly distributed posttran~plantation,~~ the failure to establish a relationship between cellular input and progenitor cell concentration postgrafting is unlikely to result from sampling errors alone. The random distribution rather suggests that autochthonous regeneration from surviving pluripotent stem cells may contribute at least partially to long-term hematopoesis.
Further implications of the results presented here concern the use of genetically altered CD34' cells for molecular replacement therapy, as long as it is questionable to what extent the autografted progenitor cells would contribute to long-term hematopoiesis. Gene marking studies are, therefore, required to address this question prospectively. For personal use only. on August 16, 2017. by guest www.bloodjournal.org From
